Study of the Safety of KSP Heptapeptide (KSP-910638G) in Humans for the Early Detection of GI Malignancies

Study of the Safety of KSP Heptapeptide (KSP-910638G)



University of Michigan

Oversight Info

Has Dmc


Is Fda Regulated Drug


Is Fda Regulated Device


Brief Summary

The purpose of this study is to evaluate the safety of orally administered KSP-910638G, a
topically administered li-cor IRDye800CW labeled heptapeptide specific for human epithelial
growth factor receptor 2 (HER2).

Detailed Description

This is a Phase IA study of the safety of an orally administered KSP-910638G heptapeptide
for detection of neoplastic tissues in multiple areas of the gastrointestinal tract in
humans. The investigators intend to enroll 25 evaluable subjects. The investigators expect
to be able to enroll about 1-2 subjects per week, so the study should take about 4-6 months
to complete.

Interested, healthy subjects ages 25-100 who respond to recruitment advertising on and appear to be eligible based responses to inclusion/exclusion
criteria questions will be scheduled for a study visit at MCRU. At the study visit, the
subjects will review and sign the informed consent and eligibility will be confirmed. If
eligible, subjects will provide a blood sample for clinical labs and a urine sample for
urinalysis. A negative urine pregnancy test for women of child-bearing potential is required
to be eligible. Eligible subjects will consume the reconstituted KSP-910638G. After 5
minutes, subjects will drink a minimum 4-8 ounces of tap water and vital signs will be
taken. Subjects will remain in MCRU for observation for 30 minutes. Vital signs will be
recorded after 30 minutes. Subjects are required to return to MCRU to have a repeat blood
draw for clinical labs and urinalysis within 24 to 48 hours after KSP-910638G ingestion. The
study team will conduct a verbal assessment for toxicity at this visit.

Overall Status

Not yet recruiting

Start Date


Completion Date


Primary Completion Date



Phase 1

Study Type


Primary Outcome


Time Frame

Number of subjects with abnormal lab values
48 hours





Intervention Type


Intervention Name


The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker known as Cy5.

Arm Group Label




Inclusion Criteria:

- Not pregnant (willing to have pregnancy test if applicable)

- No recent illness (infection, URI, virus or flu) within 2 weeks,

- Stable health status (i.e. no medication changes within 2 months, no recent surgery,
etc. per PI)

- Willing and able to sign informed consent

- Willing and able to drink the peptide and a tap water chaser

- Willing and able to get baseline and 24-48 hours post ingestion labs

Exclusion Criteria:

- Known allergy to li-cor IRDye800CW, a near infrared fluorosphore or derivatives

- Subjects on active chemotherapy or radiation therapy

- Diabetics on insulin/hypoglycemic (due to fasting requirements)



Minimum Age

25 Years

Maximum Age

100 Years

Healthy Volunteers

Accepts Healthy Volunteers

Overall Official

Last Name



Ashley E Cawthon
Study Chair
Michigan Medicine

Overall Contact

Last Name

Danielle K Turgeon, MD




Verification Date


Lastchanged Date


Firstreceived Date


Responsible Party

Responsible Party Type

Principal Investigator

Investigator Affiliation

University of Michigan

Investigator Full Name

Danielle Kim Turgeon

Investigator Title

Professor of Internal Medicine, Medical School

Has Expanded Access


Number Of Arms


Arm Group

Arm Group Label


Arm Group Type



The first three subjects will receive lyophilized powder reconstituted with 5 mL of 0.9% NaCl, 0.4 mg of KSP-910638G total. For the first three subjects, 3.34 mL of KSP-910638G will be discarded. The 1.66 mL of KSP-910638G remaining in the syringe will be administered by squirting it into the mouth of the subject. Following a safety review of these three subjects, the remaining 22 subjects will receive the full 1.2 mg dose of KSP-910638G reconstituted in 5 mL 0.9% NaCl. These 22 subjects will receive all 5 mL of the peptide solution in a syringe for administration. The agent will not be reconstituted until the subject is ready to squirt the peptide into his or her mouth via syringe. They will be asked to wait 5 minutes and then drink at least 4-8 oz of tap water.

Firstreceived Results Date


Overall Contact Backup

Last Name

Elaine M Brady, MBA




Firstreceived Results Disposition Date


Study Design Info

Intervention Model

Single Group Assignment

Primary Purpose



No masking processed this data on May 19, 2017


Conditions usually refer to a disease, disorder, syndrome, illness, or injury. In, conditions include any health issue worth studying, such as lifespan, quality of life, health risks, etc.

Interventions refer to the drug, vaccine, procedure, device, or other potential treatment being studied. Interventions can also include less intrusive possibilities such as surveys, education, and interviews.
Study Phase

Most clinical trials are designated as phase 1, 2, 3, or 4, based on the type of questions that study is seeking to answer:

In Phase 1 (Phase I) clinical trials, researchers test a new drug or treatment in a small group of people (20-80) for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.

In Phase 2 (Phase II) clinical trials, the study drug or treatment is given to a larger group of people (100-300) to see if it is effective and to further evaluate its safety.

In Phase 3 (Phase III) clinical trials, the study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.

In Phase 4 (Phase IV) clinical trials, post marketing studies delineate additional information including the drug's risks, benefits, and optimal use.

These phases are defined by the Food and Drug Administration in the Code of Federal Regulations.

© 2017 ICH GCP